Adage Capital Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $97M | Buy |
185,331
+162,105
| +698% | +$77.4M | 0.15% | 139 |
|
|
2025
Q4 | $13.5M | Sell |
23,226
-65,274
| -74% | -$33.3M | 0.02% | 592 |
|
|
2025
Q3 | $40.6M | Sell |
88,500
-287,663
| -76% | -$107M | 0.06% | 285 |
|
|
2025
Q2 | $114M | Buy |
376,163
+184,554
| +96% | +$55M | 0.19% | 102 |
|
|
2025
Q1 | $63.5M | Buy |
191,609
+171,649
| +860% | +$56.4M | 0.12% | 173 |
|
|
2024
Q4 | $6.16M | Buy |
+19,960
| New | +$5.61M | 0.01% | 693 |
|
|
2024
Q2 | – | Sell |
-10,000
| Closed | -$2.67M | – | 917 |
|
|
2024
Q1 | $2.67M | Buy |
+10,000
| New | +$2.36M | 0.01% | 759 |
|
|
2023
Q3 | – | Sell |
-50,000
| Closed | -$11.6M | – | 908 |
|
|
2023
Q2 | $11.6M | Sell |
50,000
-56,000
| -53% | -$15.2M | 0.03% | 542 |
|
|
2023
Q1 | $25.7M | Sell |
106,000
-18,391
| -15% | -$5.01M | 0.06% | 357 |
|
|
2022
Q4 | $36.1M | Buy |
124,391
+115,291
| +1,267% | +$11.3M | 0.09% | 273 |
|
|
2022
Q3 | $591K | Buy |
+9,100
| New | +$632K | ﹤0.01% | 909 |
|
|
2022
Q2 | – | Sell |
-77,331
| Closed | -$7.59M | – | 1120 |
|
|
2022
Q1 | $7.59M | Sell |
77,331
-22,669
| -23% | -$1.91M | 0.01% | 769 |
|
|
2021
Q4 | $8.47M | Hold |
100,000
| – | – | 0.02% | 741 |
|
|
2021
Q3 | $7.98M | Hold |
100,000
| – | – | 0.02% | 758 |
|
|
2021
Q2 | $9.74M | Buy |
100,000
+37,677
| +60% | +$4.46M | 0.02% | 702 |
|
|
2021
Q1 | $7.29M | Buy |
+62,323
| New | +$7.27M | 0.01% | 747 |
|
|
2020
Q1 | – | Sell |
-40,000
| Closed | -$3.64M | – | 767 |
|
|
2019
Q4 | $3.64M | Buy |
+40,000
| New | +$3.88M | 0.01% | 636 |
|
|
2019
Q2 | – | Sell |
-32,050
| Closed | -$4.01M | – | 746 |
|
|
2019
Q1 | $4.01M | Sell |
32,050
-5,000
| -13% | -$622K | 0.01% | 620 |
|
|
2018
Q4 | $4.18M | Buy |
37,050
+5,000
| +16% | +$774K | 0.01% | 623 |
|
|
2018
Q3 | $6.86M | Sell |
32,050
-17,950
| -36% | -$4.5M | 0.02% | 598 |
|
|
2018
Q2 | $14M | Sell |
50,000
-200,000
| -80% | -$35.1M | 0.03% | 489 |
|
|
2018
Q1 | $29.2M | Sell |
250,000
-201,500
| -45% | -$24.9M | 0.07% | 315 |
|
|
2017
Q4 | $41.4M | Sell |
451,500
-48,500
| -10% | -$2.77M | 0.09% | 261 |
|
|
2017
Q3 | $22.5M | Sell |
500,000
-100,000
| -17% | -$1.87M | 0.05% | 386 |
|
|
2017
Q2 | $9.76M | Buy |
600,000
+200,000
| +50% | +$3.13M | 0.02% | 571 |
|
|
2017
Q1 | $6.16M | Buy |
400,000
+50,000
| +14% | +$786K | 0.02% | 594 |
|
|
2016
Q4 | $5.21M | Buy |
+350,000
| New | +$5.62M | 0.01% | 603 |
|
Other funds holding MDGL
BBA
RI
ACA
PC
VPM
VCM
Adage Capital Partners's MDGL Position: Q1 2026 in Review
Adage Capital Partners increased its Madrigal Pharmaceuticals (MDGL) stake by 698% in Q1 2026, buying an estimated $77.4M and bringing the position to 185,331 shares worth $97M. The position accounts for 0.15% of the portfolio, ranked #139.
Adage Capital Partners first reported a position in MDGL in Q4 2016 and has held it in 27 quarters since. The position peaked at $114M in Q2 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.
- Adage Capital Partners held 185,331 shares of Madrigal Pharmaceuticals worth $97M as of Q1 2026.
- Adage Capital Partners bought 162,105 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $77.4M.
- Madrigal Pharmaceuticals made up 0.15% of Adage Capital Partners's portfolio in Q1 2026, its #139 holding.
- Adage Capital Partners first reported a position in Madrigal Pharmaceuticals in Q4 2016 and has held it in 27 quarters since.
- Adage Capital Partners's Madrigal Pharmaceuticals position peaked at $114M in Q2 2025.
- 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.
Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.